HOOKIPA Pharma

HOOKIPA's platform is built on engineered arenaviruses — specifically lymphocytic choriomeningitis virus vectors — that act as viral delivery vehicles for antigens. Unlike adenoviral or mRNA technologies, arenaviral vectors naturally trigger potent and durable CD8+ T-cell responses without the need for a strong neutralizing antibody induction. This mechanism is particularly suited to clearing chronic infections and targeting cancers that express viral antigens, such as HPV16-driven tumors. The company holds exclusive rights to this technology through its foundational patents and long-standing academic partnerships in Vienna.

Joern Aldag, the CEO and a co-founder, leads the company's overall strategy and capital allocation decisions. He brings decades of biotech executive experience, having previously served as CEO of Evotec and held board roles at several public life-science companies. Scientific direction is guided by the legacy of co-founders Rolf Zinkernagel and Hans Hengartner, though day-to-day R&D leadership sits with the internal management team. The board of directors provides governance and approval for major financing and strategic transactions.

As a clinical-stage biotech, HOOKIPA does not yet have a commercial product. Its primary sources of revenue have been collaboration agreements — most notably the hepatitis B partnership with Gilead Sciences, which includes upfront and milestone payments. The company also monetized certain non-core assets by returning rights to a self-amplifying mRNA program acquired from Gilead as part of its 2025 restructuring. Until a therapy reaches the market, HOOKIPA will continue to fund operations through equity offerings and partnership economics.

The lead clinical program targets cancers caused by human papillomavirus serotype 16, particularly oropharyngeal head and neck squamous cell carcinoma. HPV16 is also implicated in a subset of cervical, anal, and other anogenital cancers, providing a broader addressable market. HOOKIPA's therapeutic vaccine is designed to generate a T-cell response that clears HPV16-infected cells before they progress to late-stage malignancy. The company is currently evaluating the asset in a Phase 1/2 trial with registrational intent in the US and Europe.

HOOKIPA Pharma is a publicly traded clinical-stage biotechnology company, not a family office or investment vehicle. It is listed on the Nasdaq under the ticker HOOK and operates as a conventional operating company developing and commercializing immunotherapies. Its capital structure is equity-financed and subject to standard SEC reporting requirements. The firm does not manage third-party capital, family wealth, or function as an asset manager in any capacity.

The Vienna, Austria, site is the company's research and discovery hub and the birthplace of its arenavirus technology through collaborations with the University of Zurich and the Medical University of Vienna. The New York office serves as the corporate and strategic headquarters, housing executive leadership, investor relations, and US-facing clinical operations. This transatlantic structure gives HOOKIPA access to both the European academic networks that sustain its deep science and the US capital markets that fund it.

In January 2025, HOOKIPA announced a strategic refocus to concentrate resources on its HPV16 cancer program while deprioritizing earlier-stage assets and a previously acquired self-amplifying mRNA platform. The restructuring included a reduction in workforce and operational costs, with the stated goal of extending the company's cash runway into mid-2027. This move was designed to reach key clinical data readouts without requiring near-term financing. The decision was disclosed publicly in SEC filings and a corporate press release.